MCK vs STRO · P/E 20, rev $403.43B vs rev $62.0M
McKesson Corporation (MCK) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
MCK currently screens at market cap $91.30B and trailing P/E 20.3. STRO currently screens at market cap $470.8M.
Not investment advice. Open the MCK and STRO stock pages for the full models.
Not investment advice.